Core Insights - Pharvaris is hosting a virtual investor event on October 23, 2024, to discuss the unmet needs in hereditary angioedema (HAE) treatment and the potential of its drug, deucrictibant [1] - The event will feature presentations from key medical and executive personnel, followed by a live Q&A session [2] - Pharvaris is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for HAE, with ongoing Phase 3 studies for both on-demand and prophylactic treatments [3] Company Overview - Pharvaris is developing novel, oral bradykinin B2 receptor antagonists aimed at preventing and treating HAE attacks [3] - The company aims to provide effective and well-tolerated treatment alternatives for bradykinin-mediated angioedema [3] - Positive data from Phase 2 studies has encouraged Pharvaris to advance deucrictibant, with pivotal Phase 3 studies currently enrolling [3]

Core Insights - Pharvaris is set to initiate the pivotal Phase 3 clinical study, CHAPTER-3, for deucrictibant, aimed at the prophylactic treatment of hereditary angioedema (HAE) by the end of 2024 [1][2] - The company plans to expand the clinical development of deucrictibant to include acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH) as a new indication [1][3] - The CEO of Pharvaris expressed confidence in deucrictibant's potential to become a preferred therapy for HAE management, supported by new long-term extension study data [2] Clinical Development - CHAPTER-3 will evaluate the efficacy and safety of once-daily dosing of deucrictibant extended-release tablets, designed to maintain therapeutic plasma levels for over 24 hours [2][3] - The study is on track to begin by the end of 2024, with startup activities progressing as planned [2] - Data from ongoing studies indicate that deucrictibant can provide injectable-like efficacy with favorable tolerability and convenience of oral administration [3] Research Findings - A recent investigator-initiated trial at Amsterdam UMC demonstrated that deucrictibant significantly reduced mean monthly attack rates in patients with AAE-C1INH, with no severe adverse events reported [3][4] - The results from this trial support the hypothesis that deucrictibant can effectively prevent and treat AAE-C1INH, addressing an unmet medical need [4] Upcoming Events - Pharvaris will present findings at the CIIC Fall 2024 Conference, including long-term efficacy and safety data from the RAPIDe-2 and CHAPTER-1 extension studies [6] - A live conference call will be held to discuss updates and data in detail, with presentation materials available on the company's investor relations website [7] Product Overview - Deucrictibant is a novel oral bradykinin B2 receptor antagonist, developed in both extended-release and immediate-release formulations for prophylactic and on-demand treatment of HAE [8][9] - The company aims to provide effective, well-tolerated, and easy-to-administer alternatives for patients with bradykinin-mediated angioedema [9]

ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced a summary of data being presented at the ongoing 7th Bradykinin Symposium. Details of the presentations are outlined below: Long-Term Safety and Efficacy of Oral Deucrictibant for HAE Prophylaxis, a poster presentation by Marc A. Riedl, M.D., M.S. In the current ...

Core Insights - Pharvaris, a late-stage biopharmaceutical company, is focused on developing oral bradykinin B2 receptor antagonists for the prevention and treatment of hereditary angioedema (HAE) attacks [1][3] - The company announced the acceptance of two abstracts for oral presentation and ten for poster presentation at the upcoming 7th Bradykinin Symposium in Berlin, scheduled for September 5-6, 2024 [1] Presentation Details - Oral presentations include topics such as the Bradykinin Challenge Model and the efficacy of prophylactic treatment with Deucrictibant [1] - Poster presentations will cover various aspects of HAE treatment, including long-term safety and efficacy of Deucrictibant, and comparisons with standard care [1][2] Company Overview - Pharvaris aims to provide effective and well-tolerated treatment options for HAE through novel small molecules, with positive data from Phase 2 studies [3] - The company is currently enrolling participants for a pivotal Phase 3 study for on-demand treatment of HAE attacks and plans to initiate another pivotal Phase 3 study for prevention in the near future [3]

Alignment with regulatory agencies following End-of-Phase 2 meetings for the prophylactic development of deucrictibant; global startup activities of CHAPTER-3, pivotal Phase 3 study of deucrictibant for the prevention of hereditary angioedema (HAE) attacks, underway Enrollment of RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, progressing as planned Executing from a strong financial position with cash and cash equivalents of €344 million as of June 30, 2 ...

About Pharvaris All relevant documents and information relating to the annual general meeting, including the notice and agenda for the annual general meeting, are or will be made available in the "Investors" section of Pharvaris' website under "Events & Presentations". The documents will also be made available on the SEC's website at www.sec.gov. Shareholders who wish to attend the meeting should register as described in the notice and agenda for the annual general meeting. ZUG, Switzerland, June 11, 2024 ( ...

Company Overview - Pharvaris is a late-stage biopharmaceutical company focused on developing novel, oral bradykinin B2 receptor antagonists aimed at treating and preventing hereditary angioedema (HAE) attacks [4] - The company aims to provide efficacious, safe, and easy-to-administer treatment alternatives for all sub-types of HAE, both on-demand and prophylactically [4] Upcoming Events - The annual general meeting of shareholders is scheduled for June 28, 2024, at 15:00 CEST (9:00 a.m. EDT) [1] - Relevant documents and information regarding the annual general meeting will be available in the "Investors" section of Pharvaris' website and on the SEC's website [3]

Core Insights - Pharvaris presented data on deucrictibant, an oral bradykinin B2 receptor antagonist, demonstrating its effectiveness in treating hereditary angioedema (HAE) attacks, with 78.6% of participants experiencing substantial symptom resolution within 24 hours [1][2] Group 1: Clinical Efficacy - Deucrictibant achieved substantial symptom resolution in 78.6% of participants within 24 hours after a single dose, compared to 22.4% for placebo [2] - The Treatment Outcome Score (TOS) questionnaire indicated that the majority of HAE attacks treated with deucrictibant resulted in significant symptom improvement [2] - The effectiveness of deucrictibant was found to be comparable to high-efficacy injectable therapies, with higher satisfaction scores than other oral prophylactic treatments [4] Group 2: Safety and Satisfaction - The treatment satisfaction questionnaire showed that participants reported higher satisfaction with deucrictibant's effectiveness compared to placebo, driven by favorable scores across all measured subdomains [4] - The side effects and convenience scores were consistent between deucrictibant and placebo, indicating a favorable safety profile [4] Group 3: Future Developments - Pharvaris plans to publish data from ongoing open-label extensions to further establish the long-term safety and efficacy of deucrictibant [2] - The company is exploring additional indications and pipeline expansion opportunities to address unmet needs in the HAE community [2][5] Group 4: Product Information - Deucrictibant is being developed in two formulations: an immediate-release capsule for acute treatment and an extended-release tablet for prophylactic use [6] - The company aims to provide effective, safe, and easy-to-administer alternatives for all sub-types of HAE [7]

In addition to these findings, Pharvaris continues to evaluate the ever-changing treatment landscape in HAE to best address the unmet need of people living with HAE through presentation of real-world evidence of treatment behaviors. Evaluation of Treatment Satisfaction Questionnaire for Medication (TSQM) in participants in the Phase 2 CHAPTER-1 clinical study showed satisfaction with the effectiveness of deucrictibant is higher to placebo and is in-line with separate observations of high-efficacy injectable ...

ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at three upcoming congresses: the 20th Annual Congress of International Drug Discovery Science and Technology (IDDST); the 2024 Eastern Allergy Conference (EAC); and the European Academy of Allergy and Clinical Immunolog ...